Sentence examples for a asa with from inspiring English sources

Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder of lipid metabolism characterized by deficient activity of the lysosomal enzyme arylsulfatase A (ASA) with inability to degrade galactosylceramide-3 O-sulfate (sulfatide) and galactosylsphingosine-3 O-sulfate (lysosulfatide).

Of particular interest was GTCpFE, an ASA prodrug with fumarate as the ancillary pharmacophore.

There were seven (12.5%) patients with an ASA grade of 1, 40 (71.4%) with a grade of 2 and eight (14.3%) with a grade of 3. One patient did not have an ASA grade or comorbidities reported in their notes.

TXA2 is an ASA sensitive mediator with robust links to cardiac damage post-infarction and during failure [27], [28].

Data were collected from eligible patients with an ASA score of I to III scheduled for surgery with an expected duration of > 60 minutes.

These speculations are supported by data from 2005 – 2009 from the Norwegian hip fracture register, which shows an increased proportion of patients with an ASA- (American Society of Anaesthesiologists) score [ 32] of 3 (severe systemic disease) at admittance, and fewer with an ASA score of 1 and 2 (none or mild systemic disease) [ 33].

Saposin B deficiency in humans leads to sulfatide accumulation and a metachromatic leukodystrophy (MLD -like disease siMLD -likethat observediseasearylsimilarse A (ASA) deficiency, ito cognathatnzyme (17).

The diode laser vaporization group included a greater number of anticoagulant users and patients with an ASA score >3, higher PSA level, prostate volume, and catheterization prior to the operation (P=0.01).

The number of patients with an ASA 1 or ASA2 classification [ 18] undergoing a total THA or TKA, and the number of these patients receiving an allogeneic blood transfusion are reported by all Dutch hospitals and private clinics.

The current literature corroborates this finding by demonstrating an increase risk of post-operative complications in patients with an ASA of ≥ 3.

LADG for early gastric cancer is a safe and effective treatment in elderly patients aged ≥80 years with an ASA status of 1 2 and PS of 0 1.